Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06867172 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma

Study acronym: SPACE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 10, 2025 (before its estimated March 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS). The primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk. The secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.
Trial Details
NCT Number NCT06867172
Lead Sponsor Carol Davila University of Medicine and Pharmacy
Conditions
(from sponsor)		 Pancreatic Steatosis, Pancreatic Cyst, Pancreatic Adenocarcinoma
Related terms Adenocarcinoma, Cysts, Fatty Liver, Neoplasms, Pancreatic Cyst, Platelet Glycoprotein IV Deficiency
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov